Objective:

To assess the clinical efficacy and safety of pediatric Tuina in the treatment of CARAS.

Approach:

Key Findings:

• CARAS is a prevalent chronic respiratory disorder among children, significantly impairing quality of life.
• Current management relies on pharmacotherapy, which may have adverse effects and poor long-term adherence.
• Pediatric Tuina has shown promise in treating pediatric respiratory conditions but lacks rigorous trials specifically for CARAS.

Interpretation:

This study aims to assess the efficacy and safety of pediatric Tuina in improving CARAS symptoms and quality of life in children.

Limitations:

• The study is limited to a single center, which may affect generalizability.
• Assessors will be blinded to group allocation to mitigate bias.

Conclusion:

The study aims to provide evidence for a non-pharmacological Traditional Chinese Medicine intervention in the clinical management of CARAS.

Sources:

• Clinical Trial Registration
Source

Based on findings from:

Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol

Xin Yun Chia, Junhao Cai, Dan Dai, Qing Ji, Shijian Liu, Wenyi Wang, Mengran Si, Yan Yang, Ping Lu, Xiaoqiu Wang, Sijie Dang, Yi Zhong, Shuxia Wang, Guimao Wang, Bin Xiao. Frontiers In Medicine, 2026.

https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1854540/full

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.